

10th June, 2019

(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: Closure of USFDA inspection at Kurkumbh manufacturing facility

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that following the inspection by the United States Food and Drug Administration (USFDA) at the Kurkumbh manufacturing facility from 11th March 2019 to 20th March 2019, the Company has received the Establishment Inspection Report (EIR), indicating closure of the inspection.

Kindly take the above information on record.

Thanking you,

Yours faithfully,

For Cipla Limited



Karan Tanna
Associate Director
Corporate Secretarial

Prepared by: Vivek Vadwana